 
    Antonio Postigo
ICREA-IDIBAPSPublicaciones destacadas
- 
                    Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulationAutores:Referencia: Nature Communications 2023.
- 
                    Inflammatory macrophages reprogram to immunosuppression by reducing mitochondrial translationAutores:Referencia: Nature Communications 2023.
- 
                    The adaptive antioxidant response during fasting-induced muscle atrophy is oppositely regulated by ZEB1 and ZEB2Autores:Referencia: Proceedings Of The National Academy Of Sciences Of The United States Of America 2023.
- 
                    The mesodermal and myogenic specification of hESCs depend on ZEB1 and are inhibited by ZEB2Autores:Referencia: Cell Reports 2023.
- 
                    ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cellsAutores:Referencia: Gut 2019.
- 
                    ZEB1 protects skeletal muscle from damage and is required for its regenerationAutores:Referencia: Nature Communications 2019.
- 
                    Regulation of muscle atrophy-related genes by the opposing transcriptional activities of ZEB1/CtBP and FOXO3Autores:Referencia: Nucleic Acids Research 2018.
- 
                    Mitotic polarization of transcription factors during asymmetric division establishes fate of forming cancer cellsAutores:Referencia: Nature Communications 2018.
- 
                    Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting rolesAutores:Referencia: Embo Journal 2017.
- 
                    ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1Autores:Referencia: Gut 2017.
Proyectos destacados
- 
                Cooperation and competition between colorectal carcinomas (CRC) and their tumor microenvironment: Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRC.Investigador/a principal: Antonio PostigoFinanciador: Fundació Olga TorresCódigo: FUND.OLGATORRES_19_3Duración: 01/01/2020 - 31/12/2021
- 
                Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRCInvestigador/a principal: Antonio PostigoFinanciador: Asociación Española Contra el Cáncer (AECC).Código: AECC_2019Duración: 01/11/2019 - 31/10/2022
- 
                Validation of ZEB2 as a predictive predictive biomarker and potential therapeutic target in Duchenne muscular dystrophyInvestigador/a principal: Antonio PostigoFinanciador: Duchenne Parent ProjectCódigo: DPP-E-2018Duración: 16/12/2018 - 15/12/2020
